ERIKA PAULA PIZARRO: Open Payments
NPI 1619238417 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,667 in 67 payments from 10 companies in 2025. Trend: 2023 $1,005 · 2024 $2,152 · 2025 $1,667
Food & beverage: $1,667
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 11 | $357 |
| ABBVIE INC. | 16 | $343 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $252 |
| Vanda Pharmaceuticals Inc. | 14 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $140 |
| Otsuka America Pharmaceutical, Inc. | 2 | $116 |
| Lundbeck LLC | 4 | $110 |
| Alkermes, Inc. | 2 | $57 |
| Biogen, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
Products named: Auvelity, VRAYLAR, CAPLYTA, FANAPT, REXULTI, TRINTELLIX, ARISTADA, ZURZUVAE.
Industry payments across CA — which companies pay providers there.
